Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction
NCT ID: NCT05536960
Last Updated: 2024-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
41 participants
INTERVENTIONAL
2022-09-09
2023-10-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Myocardial Viability Using Multidetector Computed Tomography
NCT00285064
Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques
NCT00449306
Comparison of Coronary CT Angiography to Invasive Coronary Angiography
NCT00146887
Cardiac Computarized Tomography in Infective Endocarditis
NCT00550823
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
NCT05499637
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
68Ga-Dotatate PET/CT
These patients will undergo a 68Ga-Dotatate PET/CT scan.
68Ga-Dotatate PET/CT
One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
68Ga-Dotatate PET/CT
One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Underwent CCTA imaging within 78 weeks from the screening visit
* Either CAD-RADS 4 or higher or 0/1 on CCTA.
* Able to provide written informed consent
Exclusion Criteria
* CVD events/revascularization in history
* Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
* Chronic or recent (\< 1 month) infections and/or clinical signs of acute infection.
* History of auto-immune diseases.
* Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices.
* Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
* Elevated liver enzymes (\> 2 ULN of liver transaminases), acute liver failure or known liver disease.
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
E.S.stroes
Prof. Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Academic Medical Center
Amsterdam, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL80263.018.21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.